-+ 0.00%
-+ 0.00%
-+ 0.00%

BioRestorative Therapies To Reveal New Data At ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease And Its BioCosmeceutical Platform

Benzinga·04/30/2026 14:39:18
Listen to the news

BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announces that it will present new data at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, taking place May 6-9 in Dublin, Ireland. The Company will have two presentations at the conference: safety and blinded efficacy data from its fully enrolled, ongoing Phase 2 clinical trial in chronic lumbar disc disease, and preclinical data on its therapeutic and BioCosmeceutical exosome platform.